Fostamatinib

Evidence Level: L5

Predicted Indications: 2

Fostamatinib

Pharmacist Assessment Report

Fostamatinib: From Immune Thrombocytopenia to Autosomal Thrombocytopenia with Normal Platelets

One-Sentence Summary

Fostamatinib is a SYK inhibitor originally used to treat thrombocytopenia caused by immune destruction of platelets. The TxGNN model predicts it may be effective for autosomal thrombocytopenia with normal platelets, but there are currently 0 clinical trials and 0 publications supporting this direction. The prediction rests on computational similarity alone.

Quick Overview

Item	Content
Original Indication	Thrombocytopenia due to immune destruction
Predicted New Indication	Autosomal thrombocytopenia with normal platelets
TxGNN Prediction Score	0.9945
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 2 of 2)
Number of DINs	2 (marketed: 2)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Based on known information, fostamatinib is a SYK (spleen tyrosine kinase) inhibitor, acting through its active metabolite R406. It is approved for chronic immune thrombocytopenia, where it reduces Fc receptor-mediated platelet destruction.

The predicted indication is an inherited thrombocytopenia, so the link to the approved indication is based on disease-category similarity (both are low platelet count conditions). However, most inherited thrombocytopenias are caused by defective platelet production rather than immune destruction. A SYK inhibitor is therefore not expected to address the underlying cause.

The high TxGNN score is a computational prediction. No trials or publications support it, so this should be treated as a research question rather than an actionable lead.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available for this predicted indication.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02508052	TAVALISSE	Not specified	Not specified
02508060	TAVALISSE	Not specified	Not specified

Safety Considerations

Drug Interactions: The interaction screening returned 100 potential interactions. The most notable are:

Major: Clarithromycin
Moderate (examples): proton pump inhibitors (omeprazole, rabeprazole, dexlansoprazole), cimetidine, corticosteroids (hydrocortisone, dexamethasone, betamethasone, budesonide, triamcinolone), aprepitant, morphine, loperamide, pioglitazone, empagliflozin, alosetron, alvimopan, dolasetron, dronabinol, eliglustat

Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction has no supporting clinical trials or literature (evidence level L5). Most inherited thrombocytopenias involve impaired platelet production, not immune destruction, so the SYK-inhibition rationale is weak.

To proceed, the following is needed:

Confirmation that the specific condition has an immune-mediated or SYK-dependent component
Mechanism of action data and package insert warnings and contraindications from Health Canada
Preclinical or case-level evidence of platelet benefit in inherited thrombocytopenia
Approved indication text and dosage forms for the Canadian DINs

Note on Other Predicted Indications

The other prediction, non-syndromic esophageal malformation (score 0.9905), also has no clinical trials and only L5 evidence. It has no identifiable mechanistic rationale and is likely a TxGNN model (deep learning) artifact.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.